Metabolic dysfunction is a well-established feature of Alzheimer's disease (AD), evidenced
by brain glucose hypometabolism that can be observed potentially decades prior to the …

Introduction Deteriorating brain glucose metabolism precedes the clinical onset of
Alzheimer's disease (AD) and appears to contribute to its etiology. Ketone bodies, mainly β …

Astrocyte reactivity is a hallmark of neuroinflammation that arises with Alzheimer's disease
(AD) and nearly every other neurodegenerative condition. While astrocytes certainly …

Since it was first generally accepted that the two amino acids glutamate and GABA act as
principal neurotransmitters, several landmark discoveries relating to this function have been …

Highlights•Cytosolic channels in the myelin sheath are critical for axonal integrity.•Activity-
dependent vesicular release and transmitter signaling regulate myelination.•Glutamate …

The prevalence of Alzheimer's disease, a chronic neurodegenerative condition, is
increasing as is the need for effective treatments and preventions. The underlying pathology …

We propose that brain energy deficit is an important pre-symptomatic feature of Alzheimer's
disease (AD) that requires closer attention in the development of AD therapeutics. Our …

During pregnancy and infancy, the human brain is growing extremely fast; the brain volume
increases significantly, reaching 36, 72, and 83% of the volume of adults at 2–4 weeks, 1 …

Hypometabolism, characterized by decreased brain glucose consumption, is a common
feature of many neurodegenerative diseases. Initial hypometabolic brain state, created by …

Introduction Unlike for glucose, uptake of the brain's main alternative fuel, ketones, remains
normal in mild cognitive impairment (MCI). Ketogenic medium chain triglycerides (kMCTs) …